cyrilzakka/clinical-trials huggingface dataset:
Latin America Registry on WatchmanTM Outcomes in Real Life

Left atrial appendage (LAA) occlusion with WatchmanTM has emerged as viable alternative to anticoagulation therapy in randomized controlled trials. The device has FDA approved since 2015 and the firsts Latin American cases were performed in 2012. However, there is no real world data from Latin American experience in terms of success and outcomes.

Approximately 450 subjects will be enrolled in the study. Up to 50 sites in Latin America will participate in the study.

Primary analyses may include, but will not be limited to, the following: procedural complications, incidence of stroke and death. Descriptive statistics will be used for baseline, procedure and follow-up data collected through the registry.

Clinical history of each patient will be analyzed for a period of 6 months after the procedure according the standard practice at the enrolling centers. There will be no additional visits, nor procedures, for subjects in the registry.

Eligibility Criteria:
Inclusion Criteria:

* Patients who were eligible for a WatchmanTM device implantation according to current international and local guidelines and per physician and institution discretion.

Exclusion Criteria:

* Patient who were currently enrolled in another investigational study or registry that would directly interfere with the current study aims.
Operant H-reflex Down-conditioning of Rectus Femoris in Post-stroke Stiff Knee Gait

The investigators performed a feasibility trial of operant conditioning of spinal reflex excitability on five healthy individuals and two post-stroke individuals. The investigators found that operant conditioning of rectus femoris reflex excitability was feasible in all participants.

The investigators performed a cohort study on 7 individuals (5 healthy, 2 post-stroke) to examine the feasibility of operant down-conditioning of rectus femoris reflex excitability (i.e. H-reflex). Each individual performed 30 sessions, 6 baseline sessions with no operant conditioning (225 trials of surface electrical stimulation of the femoral nerve), followed by 24 training sessions (20 baseline trials followed by 225 trials with feedback of H-reflex magnitude). The investigators' main outcome measure was rectus femoris H-reflex magnitude. We also examined H-reflex magnitude of other quadriceps muscles.

Eligibility Criteria:
Inclusion Criteria:

* Premorbidly independent
* Mild to moderate impairment determined by standard practices per the physical therapist
* Ability to stand for 10-minute intervals unassisted
* Ability to walk for 10-minutes on a treadmill
* Reduced knee flexion during phase and SKG as determined by a clinician
* Hemiparesis
* Ability to provide informed consent

Exclusion Criteria:

* History of cerebellar stroke, multiple stroke
* History of serious lower limb musculoskeletal injury
* Functionally relevant osteoarthritis and weight-bearing restrictions
* Have condition related to claustrophobia or other MRI contraindications
* Functionally relevant cognitive impairment
* Functionally relevant vision impairment
* Took antispasmodic medication one day prior to the session
* Had Botox injection one week prior to the session
* Pregnant women
Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis

The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.

Secondly, it will be observed safety (tolerability) clinic after the administration of the drug in patients by comparing the clinical parameters and the incidence of adverse events.

Eligibility Criteria:
Inclusion Criteria:

1. Accept the Consent Form.
2. Age between 18 and 60 years, regardless of sex;
3. Agree to return to all evaluations of the study;
4. Presenting the allergic symptoms confirmed by physical examination and by laboratory tests (IgE and sensitivity to the mite Dermatophagoides pteronyssinus), which should provide a diagnosis of allergic rhinitis with mild to moderate.

Exclusion Criteria:

1. Have participated in any experimental study or have ingested any drug trial in the 12 months preceding the start of the study;
2. Made use of other medications that interfere with the regular response of the drug in the 4 weeks preceding the start of the study, such as steroids and antihistamines;
3. Be patient with sensitivity loratadine / pseudoephedrine sulfate;
4. Have any disease or anatomical abnormality in the upper airways is detrimental to the analysis of data, for example, tumors or septal deviations moderate and severe
5. Demonstrate a history of alcohol abuse, drugs or pharmaceuticals.
6. Have consumed alcohol within 48 hours prior to the period of hospitalization;
7. Have a history of liver disease or kidney disease;
8. Present framework of current asthma or recent (less than 1 year);
9. To present the severe pressure of any cause or be on medication for that;
10. Smokers or patients who stopped smoking less than 06 months;
11. Pregnant or nursing women;
12. Patients with heart disease or who use medication for the cardiovascular system that is suffering interference of the drugs studied, for example, β-blockers;
13. Patients using corticosteroids or other medicines that interact with the study drugs as monoamine oxidase;
14. Patients with a history of glaucoma, urinary retention, and hyperthyroidism;
15. Patients who have undergone facial plastic surgery that the physician's discretion, will interfere with nasal airflow
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide.

In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.

The hereditary spastic paraplegias (HSP) are a group of more than 80 inherited neurogenetic diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide. In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice.

The clinical diagnosis of HSP does not suggest anything about its molecular cause, with a wide range of outcomes dependent on the gene affected. The recent advances in HSP genetics speak to the importance of the field and the need for a more detailed study. Moreover, the relations between clinical features and genetic mechanisms are not well understood.

Given the influence of genetics on the likelihood of developing HSP as well as the complexity and diversity of the phenotypes, progress in HSP genetics will require efforts looking at relatively large samples of the HSP population. By bringing together very detailed phenotype information with high resolution DNA analyses, and using new approaches for comparing sequence information in candidate genes or looking for phenotype/genotype associations via genome-wide scanning, the investigators aim to be a leader in this emerging area of HSP research.

The aims of this study include:

1. To identify genetic findings (single nucleotide changes or copy number variants) in patients with progressive spastic paraplegia and related disorders.
2. To correlate molecular findings with HSP phenotypes.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of progressive spasticity
Effects of Muscle Fatigue and a Taping Technique on Shoulder Motion of Athletes

The purpose of this study is to investigate the effects of muscle fatigue in the scapular kinematics of overhead athletes with and without using a kinesio taping technique for facilitating lower trapezius function. The hypothesis is that the taping technique could compensate for the negative effects caused by muscle fatigue in the scapular kinematics of healthy overhead athletes.

Muscle fatigue is a potential cause of shoulder injuries in overhead athletes. Considering the important role of lower trapezius for functional scapular stability, it is suggested that a kinesio taping technique for facilitating its function could compensate for the negative effects of muscle fatigue on scapular kinematics. This is a randomized crossover study and all included athletes will be evaluated in three sessions, with a period of seven days between them: Control (fatigue protocol, without taping), Kinesio Taping (fatigue protocol with elastic taping applied with tension) and Sham (fatigue protocol with taping applied without tension). During each session, tridimensional kinematics of scapula and humerus and electromyography of serratus anterior and trapezius (upper and lower portions) muscles of dominant shoulder will be evaluated, during scaption and throwing movements, immediately before and immediately after the fatigue protocol.The changes in scapular movements (before versus after the fatigue protocol) will be compared among the sessions.

Eligibility Criteria:
Inclusion Criteria:

* Overhead athletes regularly training;
* No report of shoulder pain in the last 6 months.

Exclusion criteria:

* Previous shoulder or neck surgery;
* Previous shoulder dislocation.
Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer

The aim of this work is to compare validity between CT and MRI in detecting muscular invasion in Patients with bladder cancer.


Eligibility Criteria:
Inclusion Criteria:

* patients with urinary bladder mass

Exclusion Criteria:

* bleeding tendency ,patients had chemo , radiotherapy
Acupuncture for Post-Traumatic Stress in Combat Veterans

The objective of this study is to determine if acupuncture is an effective treatment option for treating combat Veterans with PTSD.


Eligibility Criteria:
Inclusion Criteria:

* Veteran Age 18 to 55
* DSM-5 criteria for chronic PTSD on Clinical Administered PTSD Scale (CAPS-5)
* CAPS-5 score of ≥ 26 and meeting criteria for each of 4 symptoms

Exclusion Criteria:

* Current and past six-months psychosis
* Substance dependence within 6 months (evidence of tolerance and/or withdrawal)
* Thyroid disease
* Decisional incapacity (e.g., dementia)
* Centrally acting medications that have a potential effect on biological expression (e.g., beta-blockers, opiates, and ≥10mg equivalent of diazepam/day)
* Pain levels requiring opiate medications
* Known exposure to chemicals or physical trauma that cause neuropsychiatric sequelae
* Severe depression (Beck Depression Inventory-II score ≥30)
* A diagnosed and untreated sleep breathing disorder (SBD)
* High risk of a SBD as indicated by snoring ≥50 of nights plus one of any

  1. Any witnessed apnea
  2. Feeling non-refreshed in the morning ≥50 of mornings
  3. Daytime sleepiness indicated by falling asleep with routine tasks such as watching TV or reading
* Non-response to ≥2 evidence-based PTSD treatments (adequate medication of 12 weeks or completion to PE, CPT or an intensive program)
* Treatment non-adherence indicated by stopping treatment or \>3 missed appointments in the course of PTSD EBT
* High dissociation as indicated by a score of ≥25 on the Dissociative Experiences Scale - II
* Past chronic PTSD prior to military service
* Current active psychotherapy for PTSD
* Having acupuncture in the past year
* Pregnancy
Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

The purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.


Eligibility Criteria:
Inclusion Criteria:

* male
* age ≥18 years ≤ 45 years
* healthy
* non-smoking
* BMI 18-27

Exclusion Criteria:

* abuse of drugs
* known or supposed hypersensitivity and/or contraindication against ketamine or additives
* participation of another clinical study within the last 30 days
* chronic obstructed nose breathing or nasal polyps
* dug allergy
* blood donation within the last two months
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to infection with C. diff.

Eligibility Criteria:
Inclusion Criteria:

* Willingness to sign informed consent
* Diagnosis of C. difficile infection
* Age of 18 and older

Exclusion Criteria:

* Refusal by patient to sign informed consent form
* Treatment with antibiotics 2 weeks prior to screening
* Treatment with probiotics 6 weeks prior to screening
* History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
* Postoperative stoma, ostomy, or ileoanal pouch
* Participation in any experimental drug protocol within the past 12 weeks
* Treatment with total parenteral nutrition
* Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
* Inability of patient to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Wholebody MRI In Lung Cancer StagiNg

Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in detection of nodes in patients with cell lung cancer (NSCLC).

However, the cardiorespiratory synchronization in the MRI, allowing acquisition of synchronous images with breathing and heart movements should increase the sensitivity of detection of pathologic mediastinal lymph nodes.

Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as informative as PET, while being less expensive, not radiant.

The purpose of this study is to evaluate the performance of whole-body MRI with diffusion with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are known to be less well detected by MRI) compared to PET.


Eligibility Criteria:
Inclusion Criteria:

* At least 18 years,
* Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed,
* Patient potentially eligible for curative treatment, but no no treatment started,
* Patients for whom a PET scan and MRI are planned

Non Inclusion Criteria:

* claustrophobia,
* Implantable Medical Device
* not compatible pacemaker type or heart valve, metal splinters eye)
* Pregnant or lactating women,
Cognitive Training in Heart Failure Study (CogTrain-HF)

The daily routine in clinical settings often showed cognitive impairments in patients with congestive heart failure, particularly in terms of executive functions, episodic memory, perceptual speed and attention. It is assumed that cognitive impairments in patients with congestive heart failure may lead to deficits in medication-adherence and self-care abilities, resulting in increased healthcare costs. Recent studies reported performance improvements after cognitive training that transferred to new, untrained tasks and abilities in healthy subjects across a wide range of ages. This study investigates the effects of cognitive training in patients with congestive heart failure.

Cognitive functions of patients with congestive heart failure (NYHA II-III) before (pretest) and after (posttest) cognitive-training intervention are investigated. Changes in cognitive functions are compared to changes in two control groups: 1) age and gender matched active control group 2) age and gender matched passive waiting list control group.

The neuropsychological test battery applied at pretest and posttest includes measures of episodic memory, working memory, short-term memory, executive functions, perceptual speed and intelligence. In addition, the investigators apply standardized questionnaires of self-assessed quality of life, cognitive functioning in daily life, selfcare, and psychological well-being (depression, anxiety and personality). Relevant physiological data such as ejection fraction, heartrate, N-terminal pro brain natriuretic peptide (NT-pro-BNP) as well as drug blood level are recorded.

Eligibility Criteria:
Inclusion Criteria:

* Congestive heart failure
* NYHA II-III

Exclusion Criteria:

* Psychosis
* Dementia
* Major depression
* Reanimation (\<3month)
* Patients with assist device system
Impact of Interdental Brushing on the Evolution of Supra-gingival Bacterial Flora (BACTERIB)

In France, two-thirds of adults over 35 years of age have at least a periodontal disease. The etiology is the accumulation of dental plaque, especially in interdental spaces. The cleaning of interdental spaces is particularly complex. This accumulation of dental plaque is at the origin of a modification of the bacterial flora in favor of periodontopathogenic bacteria. These pathogens can induce within the periodontal tissues an immune and inflammatory reaction that cause tissue degradation. The majority of studies focus on people over 30 years of age with gingivitis or periodontitis. However, young adults, in whom the initial or even reversible stages of periodontal disease are the most frequent, should be the preferred target of preventive measures for this pathology.

The main objective of this study is to quantify, in healthy patients, the evolution of the supragingival bacterial flora, in the interdental spaces, following the daily passage of brushes with the adapted diameter and single passage. The secondary objective is to evaluate the qualitative change in the bacterial flora (proportions of periodontal bacteria / commensal bacteria) following the interdental cleaning.


Eligibility Criteria:
Inclusion Criteria:

* having teeth at the 4 interdental sites studied (15-16, 25-26, 35-36, 45-46),
* reporting a minimum of two daily toothbrushes,
* having a good understanding of the French language,
* accepting the terms of the study and signing written informed consent,
* in good general health (opinion of the investigator) without significant clinical abnormality and medical history.

Exclusion Criteria:

* Smoking patients (daily consumption greater than or equal to 1 cigarette),
* patients with pathologies: diabetic, haemophilia, anticoagulant, platelet antiaggregant, pregnant and lactating women,
* patients with a history of periodontal treatments,
* patients with mandibular fixed orthodontic appliances and or maxillary, masticatory coefficient less than 80%,
* patients who have taken antibiotics in the past 3 months,
* patients using interdental brushes on a regular basis (more than once a week) in addition to brushing teeth or mouthwash ,
* patients at risk for infectious endocarditis,
* patients unable to answer questions,
* non-cooperative patients,
* patients requiring geographic mobility compromising evaluation.
Clinical Effect of APRF With DFDBA Compare to Collagen Membrane With DFDBA in Intraosseous Defect

to assess the effectiveness of advanced PRF in combination of Demineralized freeze-dried bone allograft (DFDBA) as compared to collagen membrane in combination with Demineralized freeze-dried bone allograft (DFDBA) treatment of non-contained periodontal intraosseous defects in stage III periodontitis patients.

Treatment of intraosseous periodontal defects represents a clinical challenge; these defects have been detected through clinical and radiographic examination in 18- 51 % of patients with periodontitis. They are often associated with persistent deep pockets and bleeding following conventional periodontal treatment. Complex regenerative periodontal therapy is advocated for management of these defects. The outcomes of regenerative periodontal therapy are positively correlated with the morphology of osseous defects. Non-contained defects are prevalent clinically and have been reported to have a low regenerative potential.

Eligibility Criteria:
Inclusion Criteria:

* Stage III periodontitis patient having at least one tooth with one wall or combined1- to 2-wall intraosseous defect ≥ 3 mm deep (assessed by trans-gingival probing, radiographic examination) with clinical attachment level (CAL) ≥ 5mm and pocket depth (PD) ≥ 6 mm.
* Defect not extending to a root furcation area
* Vital teeth
* Non-smokers.
* No history of intake of antibiotics or other medications affecting the periodontium in the previous 6 months.
* No periodontal therapy carried out in the past 6 months.
* Able to sign an informed consent form.
* Patients age between 25 and 50 years old.
* Patients who are cooperative, motivated, and hygiene conscious.
* Systemically free according to Cornell Medical Index

Exclusion Criteria:

* Pregnancy or breast feeding
* The presence of an orthodontic appliance
* Teeth mobility greater than grade I